# Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women

> **NCT00705679** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 5029 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Emtricitabine/tenofovir disoproxil fumarate
- **DRUG:** Emtricitabine/tenofovir disoproxil fumarate placebo
- **DRUG:** Tenofovir disoproxil fumarate
- **DRUG:** Tenofovir disoproxil fumarate placebo
- **DRUG:** Tenofovir 1% vaginal gel
- **DRUG:** Tenofovir placebo

## Key facts

- **NCT ID:** NCT00705679
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 5029 (ACTUAL)
- **Last updated:** 2021-10-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00705679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00705679, "Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00705679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*